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a recent study (Schrappe et al., 2008).
Should future studies demonstrate that
the concomitant use of a NOTCH1 inhib-
itor with glucocorticoids can enhance the
response of resistant leukemia, lower
doses of dexamethasone could be used
to treat such patients, sparing them from
the toxicity of intensified chemotherapy.
The protective effect of glucocorticoid
therapy against the gastrointestinal
toxicity of g-secretase inhibitors might
also renew interest in g-secretase inhibi-
tors as therapy for patients with Alz-
heimer’s disease, for whom the drugs
were first introduced to inhibit the produc-
tion of amyloidogenic b-amyloid peptides.
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Despite great advances in our understanding of tumor initiation and progression, the identity of the ‘‘cell of
origin’’ of cancer remains elusive. Two recent publications provide experimental evidence that normal intes-
tinal stem cells are the cells of origin of intestinal cancer in the mouse.Colorectal cancer (CRC) represents a
uniquemodel to studymechanismsunder-
lying tumor formation and progression.
However, notwithstanding our detailed
understanding of the initiating and rate-
limiting mutation at the APC tumor
suppressor gene and the subsequent
genetic hits that accompany the ade-
noma-carcinoma sequence, the identity
of the CRC cell of origin is still obscure.
The epithelium lining the gastrointes-
tinal (GI) tract represents a unique stem
cell niche where different cell types are
spatially organized, each dedicated to
a specific function. As recently shown by
the Clevers laboratory, intestinal stem
cells exist at the base of the crypts and,
at least in the mouse, are earmarked by
expression of the Lgr5 gene in both theproximal and distal (colon) intestinal tract
(Barker et al., 2007). These crypt base
columnar cells divide about once per
day, and their progenies, the transient
amplifying (TA) cells, divide at an even
higher rate and migrate up the crypt until
they reach its midportion, where they
differentiate into specialized intestinal
functions. When the differentiated cells
reach the top of the crypt-villus axis,
they undergo apoptosis and are shed
into the intestinal lumen. In such a hierar-
chical tissue architecture, it would be pre-
dicted that cancer cells would arise from
(epi)genetic mutations in stem or early
progenitor cells because of their long-
term proliferation capacity and their ability
to differentiate and acquire more special-
ized functions. However, an alternativeCancer Cellmodel has been proposed in which the
initial transformation occurs in an epithe-
lial cell located in the intercryptal zone
and in which the dysplastic process
proceeds downward (Shih et al., 2001).
Two recent studies have provided
evidence for normal intestinal stem cells
as the cells of origin of intestinal tumors in
the mouse (Barker et al., 2008; Zhu et al.,
2008). Barker et al. bred a floxedApc allele
into the Lgr5-Cre mouse line, which ex-
presses Cre recombinase controlled by
the endogenous Lgr5 locus, to selectively
inactivate Apc, which leads to constitutive
activation of the Wnt/b-catenin signaling
pathway in the stem cells. Within days,
these Wnt-activated stem cells generate
transformed progeny that rapidly expand
to theTAcompartment.Eventually,multiple15, February 3, 2009 ª2009 Elsevier Inc. 87
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Previewsadenomas form in the small intestine
and the colon, in agreement with the
authors’previous reportonLgr5expression
marking the stem cells of both the proximal
and distal GI tract (Barker et al., 2008).
In contrast, induction of Cre in TA cells
does not result in the formation of frank
neoplasia.
In the second study (Zhu et al., 2008),
Cre was driven by the endogenous prom-
inin (Prom1) gene, which encodes the
cancer stem cell (CSC) marker CD133
(O’Brien et al., 2007; Ricci-Vitiani et al.,
2007). The authors show that Prom1
expression is restricted to cells located
at the base of the crypt, predominantly
overlapping with the Lgr5+ stem cells in
small intestine. This specific expression
pattern is not conserved in the colon,
where differentiated cells in the crypt
also express Prom1. Lineage-tracing
experiments provided more conclusive
evidence that Prom1 specifically marks
stem cells capable of generating all of
the differentiated cell types of the small
intestine. Hence, small-intestine stem
cells located at the crypt base are
Lgr5+Prom1+, whereas stem cells of the
colon epithelium are apparently
Lgr5+Prom1. Accordingly, breeding of
Prom1-Cre mice with animals carrying
a floxed mutant allele of the b-catenin
gene resulted in massive dysplasia in the
small intestine, but in not the colon.
Overall, both of these studies provide
evidence that a small window of opportu-
nity exists for mutations in intestinal
epithelial cells to efficiently cause tumor
formation. Nevertheless, although the
vast majority of human CRCs are trig-
gered by APC mutations (and to a much
lesser extent by oncogenic activation of
b-catenin), the underlying genetic mecha-
nisms are quite different from the abrupt
loss of Apc function (or b-catenin activa-
tion) achieved by Cre-Lox technology in
the mouse. In adenomatous polyps, the
benign precursors of colorectal cancer,
the first and second hit at the APC gene
appear to be selected so as to retain
some residualb-catenin regulating activity
(Albuquerque et al., 2002). According to
this ‘‘just-right signaling’’ model, tumor
formation in the intestine requires a
specific degreeofWnt/b-catenin signaling
activation, different from the constitutive
and full-blown activation predicted to
result from totalAPC loss.Whether specific
intestinal stem and/or progenitor cells88 Cancer Cell 15, February 3, 2009 ª2009are differentially susceptible to specific
dosages of Wnt/b-catenin signaling is at
present unclear. Moreover, as the two hits
at a tumor suppressor gene occur in
a sequential fashion, one should also
consider possible selection advantages
provided to the stem cell upon the
first mutation event, i.e., before the rate-
limiting and tumor-initiating somatic hit at
the remaining wild-type allele takes place.
Indeed, individuals with heterozygous
germline APCmutations have been shown
to have pretumor intestinal crypt changes
consistentwith enhanced stemcell survival
(Kim et al., 2004).
A similar observation that the adult
stem cell represents the cell of origin of
cancer has recently been made in chronic
myeloid leukemia (CML): restricted
expression of the BCR-ABLp210 onco-
gene in the mouse hematopoietic stem
cell compartment is sufficient to induce
CML formation that recapitulates the
human disease (Pe´rez-Caro et al., 2009).
Notably, in these three studies, evidence
points to the existence of a cellular hier-
archywithin the tumors arising frommuta-
tions in stem cells. In the case of Lgr5+
initiating cells (Barker et al., 2008), TA
cells, which do not express Lgr5 but
accumulate b-catenin, are visible 5 days
after induction of the Apc mutation. In
more advanced adenomas, only 6.5% of
the tumor cells express the intestinal
stem cell marker. Likewise, only 15.5%
of tumor cells retained CD133 expression
in the prominin study (Zhu et al., 2008).
This is reminiscent of human colorectal
cancers in which CD133 was shown to
mark a subpopulation of CSCs with
tumor-initiating capacity when trans-
planted in immunodeficient recipient
mice (O’Brien et al., 2007; Ricci-Vitiani
et al., 2007). Finally, in the CML mouse
model expressing BCR-ABLp210 under
the control of the Sca1 promoter, leuke-
mogenic potential was only observed in
tumor-derived Sca1+ cells, but not in the
more mature Sca1 parenchymal cells
(Pe´rez-Caro et al., 2009). Overall, these
observations support the CSC model
that predicts a cellular hierarchy within
malignancies in which cells with self-
renewal and differentiation ability coexist
with more specialized and mature cells.
However, the CSC model has been
challenged by showing that non-CSC
subpopulations of tumor cells can also
recapitulate the diversity of the primaryElsevier Inc.cancer when transplanted in immunoin-
competent animals (Kelly et al., 2007;
Quintana et al., 2008; Shmelkov et al.,
2008). From this perspective, the
lineage-tracing experiments presented in
the Barker et al. and Zhu et al. papers
further confirm the CSC model and
bypass the limitations and experimental
variability of the transplantation assay.
How do these advancements affect our
understanding of cancer and impact on
therapeutic approaches? In the CML
model, CSC elimination was sufficient to
eradicate the whole tumor though treat-
ment with the BCR-ABL inhibitor imatinib
could not modify the course of the
disease (Pe´rez-Caro et al., 2009). Of
note, BCR-ABL oncogene activation in
CML and loss of APC function in CRC
have been shown to cause genetic insta-
bility possibly allowing escape from onco-
gene dependence by accumulating addi-
tional somatic changes in CSCs. Future
efforts should consider targeting the
CSC population as a whole rather than
focusing on pharmacological inhibition of
the molecular pathways underlying CSC
onset. One challenge ahead is to identify
cell surface markers that exclusively
mark CSCs and that can be targeted
without affecting their normal counter-
parts.
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